259 related articles for article (PubMed ID: 32423277)
41. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
[TBL] [Abstract][Full Text] [Related]
42. A narrative review on the Synchrobreathe™: A novel breath-actuated pressurised metered-dose inhaler for the treatment of obstructive airway diseases.
Lavorini F; Usmani OS; Salvi S; Rote K; Gaur V; Gogtay J
Respir Med; 2023; 219():107435. PubMed ID: 38652077
[TBL] [Abstract][Full Text] [Related]
43. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
[TBL] [Abstract][Full Text] [Related]
44. Successful use of DPI systems in asthmatic patients--key parameters.
Richter K
Respir Med; 2004 Oct; 98 Suppl B():S22-7. PubMed ID: 15481285
[TBL] [Abstract][Full Text] [Related]
45. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
Virchow JC; Weuthen T; Harmer QJ; Jones S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
[TBL] [Abstract][Full Text] [Related]
46. Influences of gender and anthropometric features on inspiratory inhaler acoustics and peak inspiratory flow rate.
Taylor TE; Holmes MS; Sulaiman I; Costello RW; Reilly RB
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():2227-30. PubMed ID: 26736734
[TBL] [Abstract][Full Text] [Related]
47. Exhalation immediately before inhalation optimizes dry powder inhaler use.
Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
[TBL] [Abstract][Full Text] [Related]
48. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment.
Panigone S; Sandri F; Ferri R; Volpato A; Nudo E; Nicolini G
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32238349
[TBL] [Abstract][Full Text] [Related]
49. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
50. [Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children].
Zhang QL; Zheng JP; Pan WH; He H; Chen GL; An JY; Yuan LF; Luo DF
Zhonghua Er Ke Za Zhi; 2008 Feb; 46(2):98-103. PubMed ID: 19099680
[TBL] [Abstract][Full Text] [Related]
51. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?
Al-Showair RA; Tarsin WY; Assi KH; Pearson SB; Chrystyn H
Respir Med; 2007 Nov; 101(11):2395-401. PubMed ID: 17629471
[TBL] [Abstract][Full Text] [Related]
52. Inspiratory muscle training may increase peak inspiratory flow in chronic obstructive pulmonary disease.
Weiner P; Weiner M
Respiration; 2006; 73(2):151-6. PubMed ID: 16155355
[TBL] [Abstract][Full Text] [Related]
53. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
54. Wixela Inhub: Dosing Performance
Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
[No Abstract] [Full Text] [Related]
55. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?
Scichilone N; Benfante A; Bocchino M; Braido F; Paggiaro P; Papi A; Santus P; Sanduzzi A
Pulm Pharmacol Ther; 2015 Apr; 31():63-7. PubMed ID: 25724817
[TBL] [Abstract][Full Text] [Related]
56. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
[TBL] [Abstract][Full Text] [Related]
57. From the infant to the geriatric patient-Strategies for inhalation therapy in asthma and chronic obstructive pulmonary disease.
Hagmeyer L; van Koningsbruggen-Rietschel S; Matthes S; Rietschel E; Randerath W
Clin Respir J; 2023 Jun; 17(6):487-498. PubMed ID: 37054701
[TBL] [Abstract][Full Text] [Related]
58. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship.
Kanabuchi K; Kondo T; Tanigaki T; Tajiri S; Hayama N; Takahari Y; Iwao K
Tokai J Exp Clin Med; 2011 Apr; 36(1):1-4. PubMed ID: 21547884
[TBL] [Abstract][Full Text] [Related]
59. An aerosol inhalation monitor would improve the accuracy of checklist assessment in drug inhalation techniques.
Lin TY; Yan DC; Wang YJ; Liang YT; Chen TL; Wan GH
Respir Med; 2023 Jan; 206():107068. PubMed ID: 36495788
[TBL] [Abstract][Full Text] [Related]
60. Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease.
Ohar JA; Ferguson GT; Mahler DA; Drummond MB; Dhand R; Pleasants RA; Anzueto A; Halpin DMG; Price DB; Drescher GS; Hoy HM; Haughney J; Hess MW; Usmani OS
Int J Chron Obstruct Pulmon Dis; 2022; 17():79-92. PubMed ID: 35023914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
